Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

A proof-of-concept study on the relationship between lifetime Estrogen exposure, menopausal transition, and neurodegeneration in women with multiple sclerosis.

Journal of the neurological sciences·2026
Same author

HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.

Journal of neurology·2026
Same author

Predictors of short-term, relapse-independent progression in multiple sclerosis: A machine learning approach based on clinical data and conventional MRI-derived features.

Journal of the neurological sciences·2026
Same author

Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.

Journal of the neurological sciences·2026
Same author

Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study.

Therapeutic advances in neurological disorders·2025
Same journal

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Assessing walking disability in multiple sclerosis.

Bernd C Kieseier1, Carlo Pozzilli

  • 1Department of Neurology, Heinrich-Heine-University, Germany. Bernd.Kieseier@uni-duesseldorf.de

Multiple Sclerosis (Houndmills, Basingstoke, England)
|June 29, 2012
PubMed
Summary
This summary is machine-generated.

This review evaluates walking assessments for multiple sclerosis (MS). The Timed 25-foot Walk (T25FW) is a reliable measure for clinical use, while longer tests assess fatigability and capacity.

More Related Videos

Home-Based Monitor for Gait and Activity Analysis
07:24

Home-Based Monitor for Gait and Activity Analysis

Published on: August 8, 2019

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

Related Experiment Videos

Last Updated: May 21, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Home-Based Monitor for Gait and Activity Analysis
07:24

Home-Based Monitor for Gait and Activity Analysis

Published on: August 8, 2019

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

Area of Science:

  • Neurology
  • Rehabilitation Medicine
  • Clinical Assessment

Background:

  • Multiple sclerosis (MS) frequently leads to progressive walking disability.
  • Objective and subjective measures are crucial for monitoring disease progression and treatment efficacy in MS patients.

Purpose of the Study:

  • To review the clinical utility of various walking assessment tools in multiple sclerosis (MS).
  • To determine the suitability of different walking tests for specific clinical applications in MS management.

Main Methods:

  • Systematic review of literature on walking assessments in MS.
  • Analysis of reliability, correlation with other measures, and clinical applicability of timed walking tests and patient-reported outcomes.

Main Results:

  • Walking assessments demonstrate high reliability and correlate with related MS measures like the 12-item Multiple Sclerosis Walking Scale (MSWS-12).
  • Shorter timed tests (e.g., Timed 25-foot Walk (T25FW)) are suitable for overall disability in clinical settings.
  • Longer tests assess fatigability and functional capacity, while the MSWS-12 captures subjective walking experiences.

Conclusions:

  • The T25FW is a well-characterized, versatile tool for assessing walking disability across a spectrum of severity in MS.
  • Different walking tests serve distinct purposes, aiding comprehensive patient evaluation.
  • Further research is needed to fully validate other objective walking assessments in MS.